(Q53234222)

12 May 2018

title

The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. (English)

1 reference

12 May 2018

author name string

Beach TG

1

1 reference

12 May 2018

Kuo YM

2

1 reference

12 May 2018

Spiegel K

3

1 reference

12 May 2018

Emmerling MR

4

1 reference

12 May 2018

Sue LI

5

1 reference

12 May 2018

Kokjohn K

6

1 reference

12 May 2018

Roher AE

7

1 reference

12 May 2018

publication date

1 April 2000

1 reference

12 May 2018

Journal of Neuropathology & Experimental Neurology

published in

1 reference

12 May 2018

volume

59

1 reference

12 May 2018

issue

4

1 reference

12 May 2018

page(s)

308-313

1 reference

12 May 2018

Mutant genes in familial Alzheimer's disease and transgenic models

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Topographical distribution of neurochemical changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Necropsy evidence of central cholinergic deficits in senile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Cholinergic markers in elderly patients with early signs of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Convergent cholinergic activities in aging and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

The effect of long-term physostigmine administration in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Long-term administration of oral physostigmine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

21 January 2018

Identifiers

DOI

10.1093/JNEN/59.4.308

1 reference

12 May 2018

1 reference

12 May 2018